Real-world studies have evaluated the use of anticoagulants in obese patients with
nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of …

Background Patients with obesity were underrepresented in studies evaluating the safety
and effectiveness of direct oral anticoagulants (DOAC) in patients with non-valvular atrial …

Abstract Background Direct oral anticoagulants (DOACs) have become favorable choices for
anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non …

Background Direct‐acting oral anticoagulants are now the preferred method of
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …

Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …

Background Limited clinical data exist describing the use of direct oral anticoagulants
(DOACs) in patient with extreme body weight. Thus, the International Society of Thrombosis …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Aims This study sought to determine the impact of weight and body mass index (BMI) on the
safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in …

Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …